Pfizer is adding follow-on biologics to pipeline

04/27/2010 | Wall Street Journal, The

Pfizer is working to boost its biotech business by developing new versions of blockbuster treatments, including formulations of blood cancer drug Rituxan and rheumatoid arthritis medicine Enbrel that require fewer injections. The company is using Trubion Pharmaceuticals' technology to tailor the "bio-betters," some of which are in midstage development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT